|
|
| | GSK 2330672 Basic information |
| Product Name: | GSK 2330672 | | Synonyms: | GSK 2330672;GSK 2330672; GSK-2330672;3-[[(3R,5R)-3-butyl-3-ethyl-7-methoxy-1,1-dioxo-5-phenyl-4,5-dihydro-2H-1λ6,4-benzothiazepin-8-yl]methylamino]pentanedioic acid;Pentanedioic acid, 3-((((3R,5R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,4-benzothiazepin-8-yl)methyl)amino)-;CS-2639;Iinerixibat;Iinerixibat (GSK2330672);linerixibat | | CAS: | 1345982-69-5 | | MF: | C28H38N2O7S | | MW: | 546.68 | | EINECS: | 604-604-1 | | Product Categories: | | | Mol File: | 1345982-69-5.mol |  |
| | GSK 2330672 Chemical Properties |
| Boiling point | 730.8±60.0 °C(Predicted) | | density | 1.218±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 5 mg/ml; DMSO: 2 mg/ml; PBS (pH 7.2): 0.2 mg/ml | | form | A crystalline solid | | pka | 3.27±0.10(Predicted) |
| | GSK 2330672 Usage And Synthesis |
| Description | GSK2330672 is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT; IC50s = 42, 2.1, and 1.9 nM for human, mouse, and rat ASBT, respectively). In vivo, GSK2330672 (0.05 mg/kg) stimulates fecal bile acid secretion, reduces hemoglobin A1c (HbA1c) and plasma glucose levels, and increases total GLP-1 and plasma insulin in Zucker diabetic fatty (ZDF) rats. |
| | GSK 2330672 Preparation Products And Raw materials |
|